Efficacy and safety of American ginseng (Panax quinquefolius L.) extract on glycemic control and cardiovascular risk factors in individuals with type 2 diabetes: a double-blind, randomized, cross-over clinical trial

European Journal of Nutrition
Vladimir VuksanMichael Z C Li

Abstract

Despite the lack of evidence, a growing number of people are using herbal medicine to attenuate the burden of diabetes. There is an urgent need to investigate the clinical potential of herbs. Preliminary observations suggest that American ginseng (Panax quinquefolius [AG]) may reduce postprandial glycemia. Thus, we aimed to evaluate the efficacy and safety of AG as an add-on therapy in individuals with type 2 diabetes (T2DM) controlled by conventional treatment. 24 individuals living with T2DM completed the study (F:M = 11:13; age = 64 ± 7 year; BMI = 27.8 ± 4.6 kg/m2; HbA1c = 7.1 ± 1.2%). Utilizing a double-blind, cross-over design, the participants were randomized to receive either 1 g/meal (3 g/day) of AG extract or placebo for 8 weeks while maintaining their original treatment. Following a ≥ 4-week washout period, the participants were crossed over to the opposite 8-week treatment arm. The primary objective was HbA1c, and secondary endpoints included fasting blood glucose and insulin, blood pressure, plasma lipids, serum nitrates/nitrites (NOx), and plasominogen-activating factor-1 (PAI-1). Safety parameters included liver and kidney function. Compared to placebo, AG significantly reduced HbA1c (- 0.29%; p = 0.041) and fast...Continue Reading

Associated Clinical Trials

References

Mar 29, 2003·Diabetes Care·Gloria Y YehRussell S Phillips
Jun 29, 2004·Diabetes Care·David E GoldsteinDavid B Sacks
Jun 16, 2005·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·Vladimir Vuksan, John L Sievenpiper
Apr 4, 2006·Journal of the American College of Nutrition·John L SievenpiperVladimir Vuksan
Jun 22, 2007·Clinical and Experimental Pharmacology & Physiology·James D Cameron, J Kennedy Cruickshank
Nov 25, 2011·Current Vascular Pharmacology·Dimitris TousoulisChristodoulos Stefanadis
Jan 1, 2012·Journal of Ginseng Research·Dong-Hyun Kim
May 16, 2014·Canadian Journal of Diabetes·William HarperJean-François Yale
Jun 4, 2014·Evidence-based Complementary and Alternative Medicine : ECAM·Iva MucaloDario Rahelić
Nov 8, 2014·Journal of Ginseng Research·Chang Ho Lee, Jong-Hoon Kim
Nov 8, 2014·Journal of Ginseng Research·Jung-Bum ParkCuk-Seong Kim
Mar 18, 2016·The New England Journal of Medicine·Marc A PfefferJeffrey L Probstfield
Mar 18, 2016·The New England Journal of Medicine·Yusuke TsutsumiTatsuyoshi Ikenoue
Mar 18, 2016·The New England Journal of Medicine·Giuseppe Derosa, Pamela Maffioli

❮ Previous
Next ❯

Citations

Nov 6, 2018·Canadian Journal of Physiology and Pharmacology·Morris Karmazyn, Xiaohong Tracey Gan
Dec 15, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Wei ChenDavid G Popovich
Mar 1, 2019·International Journal of Molecular Sciences·Mihir ParikhThomas Netticadan
Feb 8, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Michael SarheneGuanwei Fan
May 9, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Guang-Xuan ZhuShu-Qing Li

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.